{"protocolSection": {"identificationModule": {"nctId": "NCT00292461", "orgStudyIdInfo": {"id": "E2090-AS886-202"}, "organization": {"fullName": "Eisai Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures", "officialTitle": "A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures"}, "statusModule": {"statusVerifiedDate": "2009-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-03"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-02-14", "studyFirstSubmitQcDate": "2006-02-14", "studyFirstPostDateStruct": {"date": "2006-02-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-09-27", "resultsFirstSubmitQcDate": "2011-07-20", "resultsFirstPostDateStruct": {"date": "2011-08-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-05-13", "lastUpdatePostDateStruct": {"date": "2013-05-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eisai Inc.", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy and safety of zonisamide for anti-epilepsy drugs (AEDs) treated subjects with refractory simple partial, complex partial or partial with secondary generalized seizures."}, "conditionsModule": {"conditions": ["Epilepsy"], "keywords": ["Epilepsy", "seizures"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 64, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "zonisamide", "type": "ACTIVE_COMPARATOR", "description": "tablet", "interventionNames": ["Drug: Zonisamide"]}, {"label": "lamotrigine", "type": "ACTIVE_COMPARATOR", "description": "tablet", "interventionNames": ["Drug: Lamotrigine"]}], "interventions": [{"type": "DRUG", "name": "Zonisamide", "description": "Tablet once or twice daily orally for 16 weeks", "armGroupLabels": ["zonisamide"]}, {"type": "DRUG", "name": "Lamotrigine", "description": "Tablet once daily orally for 16 weeks", "armGroupLabels": ["lamotrigine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline", "description": "Percentage Change of Frequency = (T-B)/B\\*100% T= Total seizure frequency during maintenance dose period / maintenance dose period (weeks)\\* 4 B= The monthly seizure frequence with one month prior to enrollment", "timeFrame": "Baseline and 16 weeks"}], "secondaryOutcomes": [{"measure": "Global Assessment of Efficacy by Physician at the End of 16-week Treatment Period", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Global Assessment of Efficacy by Participants at the End of the 16-week Treatment Period", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Response Rate: Defined as the Percentage of Participants With >= 50% Reduction of Monthly Seizure Frequency at the End of 16-week Treatment From Baseline.", "timeFrame": "Baseline and 16 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Subjects must sign and date the informed consent form\n* Clinical diagnosis as refractory epilepsy\n\nExclusion criteria:\n\n* Progressive neurologic disease\n* Serious psychiatric disease\n* Hemolytic anemia\n* G6PD (glucose-6-phosphate dehydrogenase) deficiency\n* Acute intermittent porphyrias\n* Subjects who have received study drugs (Zonisamide, Lamotrigine) in the past\n* Drug or alcohol addiction\n* Renal impairment (serum creatinine \u2267 1.5 mg/dl), or hepatic abnormality (ALT or AST \\> 2x ULN)\n* Stevens-Johnson syndrome\n* Progressive exfoliative dermatitis\n* Pregnant, lactating or of childbearing potential female\n* Regularly taking oral contraceptives\n* Hypersensitivity to study drugs\n* Severe cardiac disease (New York Heart Association Functional Class III and IV)\n* History of malignancy within 5 years\n\n  * Taking valproic acid within 7 days prior to screening\n  * Subjects with simple partial seizures without motor component", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "maximumAge": "70 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Ya-Hui Cheng", "affiliation": "Eisai Taiwan", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Changhua Christian Hospital", "city": "Changhua", "state": "Taiwan", "country": "China"}, {"facility": "Chang-Gung Memorial Hospital (CGMH)", "city": "Kaohsiung", "state": "Taiwan", "country": "China"}, {"facility": "Chang-Gung Memorial Hospital (CGMH)", "city": "Linkou", "state": "Taiwan", "country": "China", "geoPoint": {"lat": 45.28606, "lon": 130.26151}}, {"facility": "China Medical University Hospital (CMUH)", "city": "Taichun", "state": "Taiwan", "country": "China"}, {"facility": "National Cheng Kung University Hospital", "city": "Tainan", "state": "Taiwan", "country": "China"}, {"facility": "Chang-Gung Memorial Hospital (CGMH)", "city": "Taipei", "state": "Taiwan", "country": "China"}, {"facility": "Taipei Tzu Chi General Hospital", "city": "Taipei", "state": "Taiwan", "country": "China"}, {"facility": "Taipei Veterans General Hospital", "city": "Taipei", "state": "Taiwan", "country": "China"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks"}, {"id": "FG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks"}, {"id": "BG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "64"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.3", "spread": "11.5"}, {"groupId": "BG001", "value": "35.0", "spread": "9.8"}, {"groupId": "BG002", "value": "36.8", "spread": "10.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "64"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Taiwan", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "64"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline", "description": "Percentage Change of Frequency = (T-B)/B\\*100% T= Total seizure frequency during maintenance dose period / maintenance dose period (weeks)\\* 4 B= The monthly seizure frequence with one month prior to enrollment", "populationDescription": "ITT (intent-to-treat)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "percent change", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks"}, {"id": "OG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-32.7", "lowerLimit": "-100", "upperLimit": "180.0"}, {"groupId": "OG001", "value": "-35.6", "lowerLimit": "-100", "upperLimit": "444.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.240", "statisticalMethod": "ANOVA"}]}, {"type": "SECONDARY", "title": "Global Assessment of Efficacy by Physician at the End of 16-week Treatment Period", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks"}, {"id": "OG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"title": "Greatly improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Somewhat improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "No change", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Somewhat worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Greatly worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.460", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Global Assessment of Efficacy by Participants at the End of the 16-week Treatment Period", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks"}, {"id": "OG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"title": "Greatly improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Somewhat improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "No change", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Somewhat worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Greatly worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.079", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Response Rate: Defined as the Percentage of Participants With >= 50% Reduction of Monthly Seizure Frequency at the End of 16-week Treatment From Baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks"}, {"id": "OG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.8"}, {"groupId": "OG001", "value": "45.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.860", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Zonegran", "description": "once or twice daily orally for 16 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 34, "otherNumAffected": 20, "otherNumAtRisk": 34}, {"id": "EG001", "title": "Lamotrigine", "description": "once daily orally for 16 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 30, "otherNumAffected": 20, "otherNumAtRisk": 30}], "seriousEvents": [{"term": "Lumber contusion", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "nystagmus", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}], "otherEvents": [{"term": "Disturbance in attention", "organSystem": "Nervous system disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "dizziness", "organSystem": "Nervous system disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 30}]}, {"term": "Gait disturbance", "organSystem": "Nervous system disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "insomnia", "organSystem": "Nervous system disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 30}]}, {"term": "nystagmus", "organSystem": "Nervous system disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "somnolence", "organSystem": "Nervous system disorders", "notes": "derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 30}]}, {"term": "White blood cell urine positive", "organSystem": "Investigations", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Blood alkaline phosphatase increased", "organSystem": "Investigations", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Electrocardiogram abnormal", "organSystem": "Investigations", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Hepatic enzyme abnormal", "organSystem": "Investigations", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Red blood cell urine positive", "organSystem": "Investigations", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Weight decreased", "organSystem": "Investigations", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Mood altered", "organSystem": "Psychiatric disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "nausia", "organSystem": "Gastrointestinal disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "Abdominal distention", "organSystem": "Gastrointestinal disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "anorexia", "organSystem": "Metabolism and nutrition disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "malaise", "organSystem": "General disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "splenomegaly", "organSystem": "Blood and lymphatic system disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "Hepatic function disorders", "organSystem": "Hepatobiliary disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}]}, {"term": "contusion", "organSystem": "Musculoskeletal and connective tissue disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}, {"term": "rash", "organSystem": "Skin and subcutaneous tissue disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 30}]}, {"term": "diplopia", "organSystem": "Eye disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 30}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "notes": "Derived from Table for all drug-related AEs", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Takao Ishii, Asia regulatory affaires", "organization": "Eisai Co., Ltd.", "phone": "81-3-3817-3914"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}, {"id": "D000012640", "term": "Seizures"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M12307", "name": "Neoplasm Metastasis", "relevance": "LOW"}, {"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M15452", "name": "Seizures", "asFound": "Seizures", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077213", "term": "Lamotrigine"}, {"id": "D000078305", "term": "Zonisamide"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}], "browseLeaves": [{"id": "M1949", "name": "Zonisamide", "asFound": "AZA", "relevance": "HIGH"}, {"id": "M1701", "name": "Lamotrigine", "asFound": "Muscle strength", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}